Chandler Chicco Companies Announces the Creation of Chandler Chicco Digital

NEW YORK, June 6, 2012 /PRNewswire/ -- Chandler Chicco Companies (CCC), a global health communications company and part of inVentiv Health, Inc., announced today the creation of Chandler Chicco Digital (CCD), a new division that combines Chandler Chicco's existing digital strategy services with the technology expertise of Kazaam Interactive to deliver innovative digital solutions to clients.  This follows an earlier announcement from CCC's parent company, inVentiv Health, stating that it has acquired Kazaam Interactive.

(Logo:  http://photos.prnewswire.com/prnh/20120606/LA20365LOGO)

"Kazaam uniquely marries pioneering technology expertise with a deep understanding of the pharmaceutical sector," said Bob Chandler, president and CEO of Chandler Chicco Companies and senior vice president of marketing and communications for inVentiv Health.  "With this acquisition, inVentiv Health will be able to provide its clients with comprehensive digital solutions, from strategy to technical execution."  

Kazaam's founders, information technology veterans, decided to establish Kazaam after several years in the biopharmaceutical and consumer sectors.  Their focus has been assembling a team that excels at taking high-level ideas and concepts and quickly prototyping solutions. Their expertise in platform/solution architecture allows for fast and efficient speed-to-market in development and digital curation.  In less than five years, Kazaam has developed an industry-wide reputation for doing impressive work for blue-chip clients. To date, Kazaam has worked with 60 brands.

"Both Kazaam and CCC have healthcare at their core," said Tom Marotta, president and CEO of Kazaam.  "We share a hyper-focus on client satisfaction, a commitment to innovation, a dedication to bringing real value to clients, and a passion for transforming health.  Being part of CCC, and parent organization inVentiv Health, will allow us to deploy unique, creative solutions to the market."

In addition to fully integrated social and digital programs, CCD will offer a wide range of services, including information architecture, user experience design, creative design, solution architecture and delivery, website development and hosting, CRM integration, content management systems, email marketing, campaign dashboards, site traffic reports, customer segmentation solution architecture, OpenID integration, SEO, and mobile and smartphone application development.  These offerings will complement CCC's top-flight public relations, digital/social, public affairs, corporate communications, branding, and medical education services for health and wellness clients.

Simple, elegant solutions to common communications problems in the healthcare industry underlie all of Kazaam's proprietary applications and platforms. Its approaches are rooted in first-hand understanding of the challenges facing healthcare IT departments.  Similarly, CCC programs are rooted in decades of healthcare experience and designed to help solve complex client challenges.

"Our clients know we're in the midst of a revolution in the marketing of healthcare, spurred by changing consumer expectations and fueled by technology," said Ritesh Patel, who drives digital strategy for Chandler Chicco Digital and inVentiv Health's Commercial segment.  "We've delivered digital solutions to our clients for years so this acquisition builds on CCC's legacy of award-winning digital work and positions us to deliver what clients need today and tomorrow."

Further tapping Kazaam's expertise across inVentiv Health's Clinical, Commercial and Consulting segments will allow the organization to better service client demands for cutting-edge, custom-built communications technologies and software platforms.  This enhanced capability will further complement work already being executed for inVentiv clients worldwide.

About Chandler Chicco Companies

Chandler Chicco Companies (CCC) is a global health communications group that delivers unmatched perspective and creative know-how. With an integrated approach to communications, CCC offers best-in-class capabilities spanning public relations, digital and social media, medical and scientific education, marketing and branding, graphic design and multimedia, event production and research and measurement. Companies under the Chandler Chicco umbrella include: Allidura Consumer, Brandtectonics, Biosector 2, Chamberlain Healthcare Public Relations, Chandler Chicco Agency, Chandler Chicco Digital, Chandler Chicco Productions, Determinus, Haas & Health Partner Public Relations, Ingenda Communications, Litmus Medical Marketing & Education, 'nition Design, SanCom Creative Communication Solutions (CCS), and SharedVoice PR.

CCC is part of inVentiv Health, Inc., with companies based in New York, Los Angeles, Washington, D.C., London, Paris and Eltville (Frankfurt), as well as a global healthcare network operating in 40 markets. For more information, visit www.chandlerchiccocompanies.com.

About inVentiv Health

inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced  and future acquisitions; the impact of any additional leverage we may incur in connection with the financing of acquisitions, on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memorandums provided in connection with the issuance of our senior secured notes for further discussion of these risks and other factors.

SOURCE Chandler Chicco Companies